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Abstract
Background:  The investigation of molecular mechanisms underlying transcriptional regulation,
particularly in embryonic stem cells, has received increasing attention and involves the systematic
identification of target genes and the analysis of promoter co-occupancy. High-throughput approaches
based on chromatin immunoprecipitation (ChIP) have been widely used for this purpose. However, these
approaches remain time-consuming, expensive, labor-intensive, involve multiple steps, and require
complex statistical analysis. Advances in this field will greatly benefit from the development and use of
simple, fast, sensitive and straightforward ChIP assay and analysis methodologies.
Results: We initially developed a simplified, basic ChIP protocol that combines simplicity, speed and
sensitivity. ChIP analysis by real-time PCR was compared to analysis by densitometry with the ImageJ
software. This protocol allowed the rapid identification of known target genes for SOX2, NANOG,
OCT3/4, SOX17, KLF4, RUNX2, OLIG2, SMAD2/3, BMI-1, and c-MYC in a human embryonic stem cell
line. We then developed a novel Sequential ChIP protocol to investigate in vivo promoter co-occupancy,
which is basically characterized by the absence of antibody-antigen disruption during the assay. It combines
centrifugation of agarose beads and magnetic separation. Using this Sequential ChIP protocol we found
that c-MYC associates with the SOX2/NANOG/OCT3/4 complex and identified a novel RUNX2/BMI-1/
SMAD2/3 complex in BG01V cells. These two TF complexes associate with two distinct sets of target
genes. The RUNX2/BMI-1/SMAD2/3 complex is associated predominantly with genes not expressed in
undifferentiated BG01V cells, consistent with the reported role of those TFs as transcriptional repressors.
Conclusion: These simplified basic ChIP and novel Sequential ChIP protocols were successfully tested
with a variety of antibodies with human embryonic stem cells, generated a number of novel observations
for future studies and might be useful for high-throughput ChIP-based assays.
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Background
Regulatory transcription factors (TFs) are encoded by
approximately 10% of the human genome [1]. The search
for an accurate and complete list of target genes for thou-
sands of TFs and the elucidation of their complex interac-
tions at promoter sites, particularly in embryonic stem
(ES) cells, has gained increasing interest. However, only a
small fraction of the in vivo target genes and relatively few
TF-TF interactions have been elucidated [2-4]. Chromatin
immunoprecipitation (ChIP) and its derivatives (ChIP-
chip, ChIP-seq, ChIP-SAGE, ChIP-PET, Sequential ChIP,
etc) have been widely used for the investigation of TF-
DNA interactions [4-9]. High-throughput approaches,
such as ChIP-chip and ChIP-SAGE, are necessary for
genome-wide analysis and the systematic identification of
new DNA-binding sequences. Real-time (rt) PCR remains
extensively used for validation of genome-wide data and
for analysis of ChIP results in general. High-throughput
approaches are time-consuming, expensive, labor-inten-
sive, involve multiple steps that facilitate error introduc-
tion, and require complex statistical analysis [7,10].
Therefore, advances in this field will greatly benefit from
the development and use of faster and straightforward
ChIP assay and analysis methodologies.
Here, we present data obtained with a simplified, basic
ChIP assay and analysis protocol that allowed the rapid
identification of known target genes for SOX2, NANOG,
OCT3/4, SOX17, KLF4, RUNX2, OLIG2, SMAD2/3, BMI-
1, and c-MYC in the human ES cell line BG01V. We used
rtPCR to initially validate the protocol/antibodies and
densitometric analysis of PCR results with the ImageJ soft-
ware as a more practical, less expansive, less time-consum-
ing readout alternative. In addition, we developed a
novel, non-disruptive, highly sensitive Sequential ChIP
protocol for the identification of promoter co-occupancy,
based on our simplified basic ChIP protocol. The data
obtained with this Sequential ChIP protocol are consist-
ent with data previously obtained with more labor-inten-
sive, expensive, time-consuming ChIP-chip platforms.
Furthermore, Sequential ChIP analysis led to the identifi-
cation of two TF complexes in BG01V ES cells: SOX2/
NANOG/OCT3/4/c-MYC and RUNX2/BMI-1/SMAD2/3
complexes. These two TF complexes associate with two
different sets of target genes. The RUNX2/BMI-1/SMAD2/
3 complex is associated predominantly with genes not
expressed in undifferentiated BG01V cells, consistent with
the reported role of those TFs as transcriptional repressors.
These simplified basic ChIP and novel Sequential ChIP
protocols were successfully tested with a variety of anti-
bodies with BG01V ES cells, generated a number of novel
observations for future studies and might be useful for
high-throughput ChIP-based assays.
Results
Development of an improved basic ChIP protocol
We developed a simplified, basic ChIP protocol (diagram
in Fig. 1) and test its usefulness with antibodies against
TFs expressed in the human ES cell line BG01V. These
antibodies included those against SOX2, NANOG, OCT3/
4, SOX17, RUNX2, OLIG2, SMAD2/3, KLF4, BMI-1, and
c-MYC. This basic ChIP assay is characterized by the com-
bination of simplicity (several steps from conventional
ChIP protocols were eliminated), speed (ChIP assay per-
formed in about 2 hours; Fig. 1) and sensitivity (target
genes easily detected with 20,000 cells or less). Recently
described, commonly used protocols [11,12] normally
take longer time or lack one or more of those characteris-
tics. ChIP assays were performed with previously charac-
terized antibodies [13] and known target genes and
initially analyzed by rtPCR. We also analyzed the PCR
results by densitometry using the ImageJ software, reduc-
ing time and resources for defining PCR parameters and,
therefore, significantly decreasing experimental costs. Tar-
get genes included FGF4, LEFTY, NANOG, VEGF, BCL2,
GLI1,  E-CADHERIN,  OCT3/4,  c-MYC,  HESX1,  ZFP206,
and  SUZ12  (SOX2/NANOG/OCT3/4 targets), LAMA1
(SOX17),  B2R  (KLF4),  HOXC13  (BMI-1),  c-MYC  and
GLI1  (SMAD2/3),  P21  (OLIG2) and VEGF  and  BAX
(RUNX2). All primer sets have been validated previously
(Table 1) [14-37]. Normal IgG and input DNA (0.1% of
whole cell lysate) were used as negative controls.
The undifferentiated human ES cell line BG01V, used
throughout this study, shows NANOG expression and
nuclear localization (Fig. 2A, merged image), as expected
[38]. SOX2 and OCT3/4 expression and nuclear localiza-
tion was also verified (data not shown). Fig. 2B shows fold
enrichment relative to input DNA, as determined by
rtPCR analysis, of three known SOX2/OCT3/4/NANOG
target genes (OCT3/4, NANOG, and FGF4) [10,39] from
SOX2/OCT3/4/NANOG ChIP assays. Fig. 2C depicts PCR
results using 28 candidate targets and Fig. 2D shows fold
enrichment, as determined by densitometric analysis, of
the PCR results (Fig. 2C), of the three abovementioned
known targets (OCT3/4, NANOG, and FGF4) and addi-
tional known SOX2/OCT3/4/NANOG targets (LEFTY,
VEGF,  BCL2,  GLI1,  E-CADHERIN,  c-MYC,  HESX1,
ZFP206, and SUZ12) [10,39]. Figs. 2C and 2D also suggest
HOXC13, PTEN and BAX as novel putative SOX2/OCT3/
4/NANOG targets in undifferentiated BG01V cells (only
positively detected promoters are shown in the graph).
These results indicate that the described ChIP assay and
analysis protocol are suitable for ChIP screening. Moreo-
ver, the results also suggest that the densitometric quanti-
fication of PCR results using the ImageJ software can be
used as an alternative ChIP readout, reducing experimen-
tal time and resources.BMC Biotechnology 2009, 9:59 http://www.biomedcentral.com/1472-6750/9/59
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To further confirm the usefulness of the protocol and test
its applicability, ChIP assays were performed with addi-
tional ES cell TFs and their known target genes. Expression
and nuclear localization of all these TFs were verified
(data not shown). SOX17 plays critical roles in develop-
ment regulation, stem cell function and is required for
endoderm specification and maintenance in the embryo
[40]. As expected [41] the mouse Lama1 promoter was
detected by rtPCR and densitometric analysis (Fig. 3A)
from SOX17 ChIP assays using endoderm differentiated
mouse D3 ES cells. RUNX2, linked to bone development
and maintenance [42], regulates VEGF and BAX [31,43],
which were detected by rtPCR and densitometric analysis
(Fig. 3B) from RUNX2 ChIP assays using undifferentiated
BG01V cells. KLF4, implicated in transcriptional repres-
sion in smooth muscle cells, kidney development, stem
cell self-renewal and pluripotency [33,44,45], regulates
OCT3/4, NANOG, and B2R [33,45], which were detected
by rtPCR and densitometric analysis (Fig. 3C) from KLF4
ChIP assays using undifferentiated BG01V cells.
BMI-1, implicated in cell proliferation and stem cell self-
renewal [46,47], binds to the HOXC13 promoter [21],
which was detected by rtPCR and densitometric analysis
(Fig. 3D) of BMI-1 ChIP assays using undifferentiated
BG01V cells. SMAD2/3, involved in epithelial-to-mesen-
chymal transition, neuronal differentiation, and chondro-
genesis [29,48-50], have been shown to regulate c-MYC
and GLI1 [50], which were also detected by rtPCR and
densitometric analysis of SMAD2/3 ChIP assays using
undifferentiated BG01V cells (Fig. 3E). OLIG2, implicated
in neuron, astrocyte and oligodendrocyte differentiation,
binds to the P21 promoter [51], which was detected by
rtPCR and densitometric analysis (Fig. 3F) of OLIG2 ChIP
assays using undifferentiated BG01V cells.
As an additional negative control, an antibody against
PDX1, which is involved in pancreatic organogenesis [52],
was also used in ChIP assays. As expected [52] PDX1 was
not detected by immunofluorescence in undifferentiated
BG01V cells (data not shown). Consistently, a know
PDX1 target gene, insulin [52], could not be detected
above background by rtPCR in PDX1 ChIP assays per-
formed with undifferentiated BG01V cells (Fig. 4A). In
addition, our basic ChIP protocol was directly compared
to a previously described [20] commonly used ChIP pro-
tocol, using three of the above mentioned antibodies and
their target genes. Fig. 4B shows that our basic ChIP pro-
Table 1: Primer sets used in PCR/rtPCR reactions.
Promoter Primer sequences (Forward/Reverse) Reference
NANOG GTCTTTAGATCAGAGGATGCCCC/CTACCCACCCCCTATTCTCCCA [14]
c-MYC GAAGCCTGAGCAGGCGGGGCAGG/GCTTTGATCAAGAGTCCCAG [15]
BCL-X CTGCACCTGCCTGCCTTTGC/GGAGAGAAAGAGATTCAGGA [16]
P21 CCAGCCCTTGGATGGTTT/GCCTCCTTTCTGTGCCTGA [17]
SUZ12 TCACCCTACCCTGGCCTCGCT/TCGCTAAACCGCTCGCTGGGT [18]
MUC4 AAACTAGGGACTCCTACTTG/GGACAGAATGGGGTGAAT' [19]
FOS GGCGAGCTGTTCCCGTCAATCC/GCGGGCGCTCTGTCGTCAACTCTA [20]
HOXC13 TGCAGCGGAGCGAGCCCC/TCAACAGGGATGAGCGCGTCGTG [21]
GLI1 CTCGCGGGTGGTCCGGGCTTG/CCGCCTGCCCCCCCTTCTCA [22]
BCL2 CAGTGGGTGGCGCGGGCGGCA/CCCGGGAGCCCCCACCCCGT [23]
E-CADHERIN (CDH1) TAGAGGGTCACCGCGTCTAT/TCACAGGTGCTTTGCAGTTC [24]
OCT3/4 TGAACTGTGGTGGAGAGTGC/AGGAAGGGCTAGGACGAGAG [14]
FGF4 GGGAGGCTACAGACAGCAAG/CTGTGAGCCACCAGACAGAA [14]
LEFTY AAGCTGCAGACTTCATTCCA/CGGGGGATAGATGAAGAAAC [14]
VEGF CCTCAGTTCCCTGGCAACATCTG/GAAGAATTTGGCACCAAGTTTGT [25]
SNAIL GGCGCACCTGCTCGGGGAGTG/GCCGATTGCCGCAGCA [26]
PTEN CCGTGCATTTCCCTCTACAC/GAGGCGAGGATAACGAGCTA [27]
SMA AGCCAAGCACTGTCAGGA/ACAATGGATGGGAAAACAG [28]
COL2A TTCCAGATGGGGCTGAAAC/ATTGTGGGAGAGGGGGTCT [29]
GATA4 ACAGGAGATGGGAAGTGTCGC/GGTGACCTCTTGGGCTCAACTC [30]
GATA6 CATTTCCAGTCCCTTTTGCCC/TTCCACATCAGTCGTGTCCGAG [30]
BAX ACAGTGGCTCACGCCTGTAAT/AGCCTCCCAAGTAGCTGGAATTG [31]
TGFB GTGCAGCAAAAGAGGCTGCGTGCG/TCTATTTCTCTCTGCTGAAAT [32]
B2R GCAGAGCGGAGAGCGAAGG/GCCTGATGTCCCCACCGTC [33]
IL2 CGTTAAACAGTACCTCAAGCTCAA/CCTTTTTATCCACACAAAGAGCTA [34]
ZFP206 CCGGCCAGATTTCACTAAAGAGC/CCTACCCCATGAAATTTTGCCAG [35]
GAPDH GTGTTCCTACCCCCAATGTGT/ATTGTCATACCAGGAAATGAGCTT [14]
HESX1 GTGTTCATTGACATGCTAA/GGACCAGAAGAAAGACTGTG [36]
mouse Lama1* CCTCAGCTCCAAGAAAGGAG/AGGATGCTTCCCTGAAATCC [37]
* All others are human genes.BMC Biotechnology 2009, 9:59 http://www.biomedcentral.com/1472-6750/9/59
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tocol leads to higher fold enrichment, compared to IgG
controls, than the fold enrichment obtained with a previ-
ously described [20] commonly used ChIP protocol.
Finally, to add experimental evidence for the applicability
of the densitometric analysis of ChIP results using the
ImageJ software, OLIG2 ChIP assays were performed with
serially diluted template and primers. Fig. 4C shows that
ImageJ measurements of P21 promoter signals from these
OLIG2 ChIP assays are within a logarithmic range.
Taken together, these results confirm that our simplified,
basic ChIP assay can be used with a variety of antibodies
and that the densitometric quantification of PCR results
using the ImageJ software can be used as an alternative
ChIP readout.
SOX2/OCT3/4/NANOG/c-MYC complex co-occupies 
several promoters in BG01V cells
We then sought to examine TF-TF interactions at promoter
sites (promoter co-occupancy) using a newly developed
Sequential ChIP assay (diagram in Fig. 5), which is based
on the simplified basic ChIP assay. ChIP-chip studies have
identified numerous promoters co-occupied by the SOX2/
OCT3/4/NANOG complex [10,39]. To validate the effec-
tiveness of the Sequential ChIP assay we selected a
number of SOX2/OCT3/4/NANOG known targets and
subjected these targets to our new protocol.
The data obtained with the Sequential ChIP assay in
undifferentiated BG01V cells is consistent with previously
reported ChIP-chip data [10,39]. First, these three TFs
(SOX2/OCT3/4/NANOG) have been reported to co-
occupy the OCT3/4, NANOG, HESX1 and VEGF promot-
ers [10,39], and consistent with that, any combination of
those TFs antibodies in the Sequential ChIP assay led to
the detection of those promoters (Fig. 6A). Second, only
SOX2 and OCT3/4 co-occupy the SUZ12 promoter [10],
and consistent with that, only immunoprecipitation with
the SOX2 antibody followed by the OCT3/4 antibody
lead to the detection of the SUZ12 promoter (Fig. 6A,
middle panel, "Sequential ChIP: SOX2 > OCT3/4"),
whereas other antibody combinations did not. A SOX2
regular ChIP assay was used as a positive control (Fig. 6A).
SOX2/OCT3/4NANOG and c-MYC have been found to
share a large number of target genes in ChIP-chip studies
[10,39,53-55]. We then investigated if c-MYC co-occupies
promoters with the SOX2/OCT3/4/NANOG complex.
Indeed, immunoprecipitation with the SOX2 antibody
followed by the c-MYC antibody led to the detection of a
number of promoters in undifferentiated BG01V cells
(Fig. 6B, top panel, "Sequential ChIP: SOX2 > c-MYC").
The same promoters were detected if the NANOG anti-
body preceded the c-MYC antibody (Fig. 6B, middle
panel, "Sequential ChIP: NANOG > c-MYC") or if the
Simplified, basic ChIP protocol schematic representation Figure 1
Simplified, basic ChIP protocol schematic representation.
Sample
Aliquot saved 
as Input DNA
Formaldehyde cross-linking (15 min)
Washing with magnet (4x, 15 min)
DNA purification with silica columns (10 min) rtPCR validation
Sonication (15 min)
Ultrasonic bath incubation (15 min)
Incubation with Streptavidin magnetic beads (30 min)
PCR
ImageJ (densitometry) analysis
Dilution buffer and biotinylated-antibody
Quenching with Glycine (5 min) 
Resuspension in Lysis buffer (10 min) 
Incubation with Chelex-100 (boiling, 10 min)BMC Biotechnology 2009, 9:59 http://www.biomedcentral.com/1472-6750/9/59
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Identification of SOX2/NANOG/OCT3/4 target genes using the simplified, basic ChIP protocol Figure 2
Identification of SOX2/NANOG/OCT3/4 target genes using the simplified, basic ChIP protocol. (A) NANOG 
expression by immunocytochemistry (red), DAPI (green) and merged images of undifferentiated BG01V human embryonic 
stem cells (magnification = 20×). (B) rtPCR data from SOX2/NANOG/OCT3/4 ChIP using primers to previously known target 
genes. (C) PCR results from the indicated ChIP assays with undifferentiated BG01V cells. (D) Densitometric analysis of ChIP 
data shown in C, obtained with ImageJ software. Three independent experiments were performed. Representative results are 
shown. Fold enrichment = ChIP/Input DNA. Error bars represent standard deviation.
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OCT3/4 antibody preceded the c-MYC antibody (data not
shown). In contrast, none of these promoters were
detected when normal IgG was used as the first antibody
(Fig. 6B, last panel).
These results indicate that, at the indicated promoters
(Fig. 6B), c-MYC is a subunit of the SOX2/OCT3/4/
NANOG complex in undifferentiated BG01V cells. To fur-
ther test this hypothesis we immunodepleted SOX2 from
undifferentiated BG01V cells lysates (Fig. 6C, ERK1/2 as
negative control) and then analyzed c-MYC targets by
ChIP. Fig. 6D shows which c-MYC-bound promoters were
detected in those SOX2-depleted lysates and shows a sig-
nificant reduction in the number of c-MYC-associated
promoters. Most of the promoters detected in Fig. 6B top
panel ("Sequential ChIP: SOX2 > c-MYC") were not
detected by c-MYC ChIP after SOX2 depletion (Fig. 6D),
including P21, FGF4, NANOG, VEGF, PTEN, BAX, MUC4,
OCT3/4  and  SUZ12  (densitometric analysis confirmed
that these signals were above input DNA levels in Fig. 6B
but not in Fig. 6D, data not shown).
Identification of known target genes for a variety of stem cell transcription factors using the simplified, basic ChIP protocol Figure 3
Identification of known target genes for a variety of stem cell transcription factors using the simplified, basic 
ChIP protocol. (A) Mouse Lama1 detection from SOX17 ChIP using endoderm differentiated D3 mouse embryonic stem 
cells. (B) VEGF and BAX detection from RUNX2 ChIP. (C) OCT3/4, NANOG, and B2R detection from KLF4 ChIP. (D) HOXC13 
detection from BMI-1 ChIP. (E) c-MYC and GLI1 detection from SMAD2/3 ChIP. (F) P21 detection from OLIG2 ChIP. (A) - (F): 
Fold enrichment = ChIP/Input DNA. Error bars represent standard deviation. (B-F): using undifferentiated BG01V human 
embryonic stem cells.
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Collectively these results corroborate the applicability of
the novel Sequential ChIP assay. In addition these results
indicate that c-MYC associates with the SOX2/OCT3/4/
NANOG complex in BG01V cells.
RUNX2/BMI-1/SMAD2/3 complex co-occupies a second 
set of promoters in BG01V cells
We then sought to investigate the presence of other TF
complexes in BG01V cells using the Sequential ChIP
assay. In a screening with 25 potential target genes, we
found that BMI-1, RUNX2, SMAD2/3, KLF4 and OLIG2
bind to a similar set of promoters in BG01V cells (data not
shown). Therefore, we use this group of TFs in Sequential
ChIP assays. Seven of the promoters that were detected by
most or none of those TFs were selected for this set of
experiments. Our results indicate that IFNG,  E-CAD-
HERIN, and BAX promoters are co-occupied by a BMI-1/
RUNX2/SMAD2/3 complex, and that the SMA promoter
is co-occupied by BMI-1/SMAD2/3 (Fig. 6E). The GATA4
promoter was not detected in any of the individual ChIP
assays for this group of TFs (data not shown) and was used
as an additional negative control. Consistently GATA4
was not detected by Sequential ChIP using any combina-
tion of antibodies (Fig. 6E). In addition, MUC4 was not
detected when BMI-1 was the first antibody in the Sequen-
tial ChIP assay (Fig. 6E), as expected, since MUC4 is not
detected in BMI-1 ChIP assays (data not shown). Further-
more, Fig. 6E shows that SNAIL was not detected when
the BMI-1 antibody was followed by RUNX2 or SMAD2/
3 antibodies, which was also expected, since SNAIL was
detected in BMI-1 ChIP assays, but not detected in RUNX2
or SMAD2/3 ChIP (data not shown). None of the above
mentioned promoters were detected when the BMI-1 anti-
body was followed by the SOX2 antibody (Fig. 6E) or by
the KLF4 or OLIG2 antibodies (data not shown). Finally,
none of the above mentioned promoters were detected
when the SMAD2/3 antibody was followed by the KLF4 or
OLIG2 antibodies (data not shown).
Overall, these experiments suggest the presence of a
RUNX2/BMI-1/SMAD2/3 complex at the above men-
tioned promoters in undifferentiated BG01V cells.
Discussion
Results shown here indicate that our simplified, basic
ChIP and the novel Sequential ChIP assays are suitable for
Specificity and applicability of the simplified, basic ChIP protocol Figure 4
Specificity and applicability of the simplified, basic ChIP protocol. (A) As an additional negative control, the insulin 
promoter could not be detected from PDX1 ChIP assays using undifferentiated BG01V human embryonic stem cells. (B) The 
simplified, basic ChIP protocol (ChIP 1) was directly compared to previously described [20] commonly used ChIP protocol 
(ChIP 2), using three different antibodies (SOX17, BMI-1, OLIG2) and their respective known target genes (Lama1, HOXC13, 
p21). (C) ImageJ measurements (mean gray values) of PCR products from OLIG2 ChIP assays (p21 promoter detection), using 
a serial dilutions of DNA sample (from OLIG2 ChIP) and p21 promoter primers (logarithmic curve was added to the bar 
graphic). Fold enrichment = ChIP/Input DNA. Error bars represent standard deviation.
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systematic target gene identification and detection of TF
interactions at specific DNA sites. The suitability of the
basic ChIP assay was confirmed by our ability to rapidly
identify known targets of SOX2/OCT3/4/NANOG (FGF4,
LEFTY,  NANOG,  VEGF,  BCL2,  GLI1,  E-CADHERIN,
OCT3/4,  c-MYC,  HESX1,  ZFP206, and SUZ12)
[10,35,36,39], SOX17 (mouse Lama1) [41], RUNX2
(VEGF and BAX) [31,43], KLF4 (OCT3/4, NANOG, B2R)
[33], BMI-1 (HOXC13) [21], SMAD2/3 (VEGF, IFNG and
FOS) [50], and OLIG2 (P21) [51].
The basic ChIP protocol used here is a simplified, com-
bined version of fast ChIP protocols previously described
[11,12]. The main advantages of this basic ChIP assay over
previously published conventional protocols [[20,31,37],
for example] is the combination of speed (only about 2
hours to obtain ChIP samples, via the elimination of
some common steps) and sensitivity (known targets
could be detected with only about 20,000 cell equivalents
were used per PCR reaction). Our basic ChIP protocol
combines biotinylated antibodies, streptavidin magnetic
beads, chelating resin for elimination of PCR inhibitors
[11], and DNA purification with commercially available
silica columns. It differs from previously described fast
ChIP protocols [11,12] by not involving: antibody cap-
ture with protein A, cross-linking reversal, proteinase K
treatment and phenol-chloroform-ethanol treatment for
DNA isolation. In preliminary experiments we noticed
that the combination of chelating resin [11] and silica col-
umns for DNA purification leads to greater PCR products
yields than with chelating resin alone (data not shown).
The biotin-streptavidin interaction represents one of the
Sequential ChIP assay schematic representation Figure 5
Sequential ChIP assay schematic representation.
Basic ChIP
Sequential ChIP
Sample
Aliquot saved 
as Input DNA
Formaldehyde cross-linking (15 min)
Washing with microcentrifuge (4x, 15 min)
DNA purification with silica columns (10 min)
Sonication (15 min)
Cold room incubation (2 hrs to overnight)
Incubation with Protein G-agarose beads (30 min)
PCR
ImageJ (densitometry) analysis
Dilution buffer and 1st Antibody
Quenching with Glycine (5 min) 
Resuspension in Lysis buffer (10 min) 
Incubation with Chelex-100 (boiling, 10 min)
Dilution buffer and 2nd Antibody (biotinylated)
Cold room incubation (2 hrs to overnight)
Incubation with Streptavidin magnetic beads (30 min)
Washing with magnet (4x, 15 min)BMC Biotechnology 2009, 9:59 http://www.biomedcentral.com/1472-6750/9/59
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Identification of SOX2/OCT3/4/NANOG/c-MYC and RUNX2/BMI-1/SMAD2/3 as complexes in BG01V cells using the novel  Sequential ChIP protocol Figure 6
Identification of SOX2/OCT3/4/NANOG/c-MYC and RUNX2/BMI-1/SMAD2/3 as complexes in BG01V cells 
using the novel Sequential ChIP protocol. (A) Detection of promoter co-occupancy by SOX2/OCT3/4/NANOG, with 
the indicated combinations of antibodies. (B) Detection of promoter co-occupancy by SOX2/OCT3/4/NANOG/c-MYC, with 
the indicated combinations of antibodies. (C) SOX2 immunodepletion of BG01V lysates by three subsequent rounds of SOX2 
immumoprecipitation, using ERK1/2 as a negative control. (D) c-MYC ChIP assays results using SOX2-depleted or non-
depleted BG01V human embryonic stem cell lysates. (E) Detection of promoter co-occupancy by BMI-1/RUNX2/SMAD2/3, 
with the indicated combinations of antibodies.
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strongest non-covalent interactions known [56] and
therefore it represents an advantage over protein A-IgG
interaction [11]. Our preliminary observations (data not
shown) and those reported by other investigators [11,12]
suggest that cross-linking reversal and proteinase K treat-
ment can be avoided, although it might result in a slightly
lower DNA yield. The boiling of the samples with chelat-
ing resin and subsequent DNA purification with silica col-
umns seem to replace the need for cross-linking reversal
and proteinase K treatment.
The use of densitometric analysis of PCR results qualita-
tively matched the rtPCR results for all the antibodies used
here since all above mentioned known targets were
detected above background by both densitometry and
rtPCR (Figs. 2 and 3). Densitometric analysis with the
ImageJ software, due to its simplicity, practicality and less
time and resources used in preliminary calibration exper-
iments, offers a viable alternative to rtPCR when absolute
quantification is not required. In addition, it can be
applied for pre-screenings prior to rtPCR. It was expected,
however, that densitometric analysis with the ImageJ soft-
ware would show a quantification limitation, probably
coming from pixel saturation in DNA bands from PCR
reactions and consequent lower measurement capacity.
Such limitation probably caused the lower levels of fold
enrichment observed in the densitometric analysis as
compared to rtPCR for some of the ChIP assays (Fig. 3;
KLF4, BMI-1 and OLIG2 ChIP assay). However, our com-
parisons indicate that when the goal is simply the identi-
fication of target genes, densitometric analysis provides a
reliable alternative, besides, for some antibodies, such
limitation was minimum (Fig. 3; SOX17 and SMAD2/3
ChIP assays).
We then analyzed promoter co-occupancy using the
newly developed Sequential ChIP assay (diagram in Fig.
5). This assay provides a significant improvement from
previously described Sequential ChIP assays [57-60] and
it differs from those in two main aspects. First, during the
Sequential ChIP assay the antibody-antigen interaction is
never disrupted by epitope-specific peptides or other treat-
ments, and consequently immunoprecipitations can be
carried-out in the same, intact samples. This feature might
contribute for lower background, higher specificity and
the possibility of using smaller samples. Second, the mod-
ifications introduced in the basic ChIP assay to make it a
straightforward, fast, sensitive assay, were maintained in
the Sequential ChIP protocol. In addition, the Sequential
ChIP combines two methods of physical separation of the
targeted DNA fragments. The first antibody, non-bioti-
nylated, binds to agarose beads, via protein G-IgG interac-
tion, and is brought down by centrifugation. The second
antibody, this time a biotinylated one, binds to magnetic
beads, via biotin-streptavidin interaction, and is separated
from the rest of the sample with a magnet. These two
forms of physical separation (gravity versus magnetism)
are quite complementary and exert minimum interference
over each other. The results are even visual with the rea-
gents used here: when the antibodies used in the assay rec-
ognize TFs that co-occupy a significant number of target
genes, as it is the case for SOX2/OCT3/4/NANOG/c-MYC,
one can see the agarose beads slurry attaching to the mag-
net in the last steps of the assay, since they are carried by
the streptavidin-magnetic beads. This visual effect is not
observed with any of the negative controls. In proof-of-
principle experiments we investigated promoter co-occu-
pancy in undifferentiated BG01V cells using SOX2, OCT3/
4 and NANOG antibodies (Fig. 6A) and the obtained
results are consistent with those obtained in ChIP-chip
studies [10,39].
Furthermore, our Sequential ChIP assay identified c-MYC
as a potential interacting partner of the SOX2/OCT3/4/
NANOG complex at several gene promoters in undifferen-
tiated BG01V cells (Fig. 6). It has been suggested that c-
MYC is involved in the regulation of up to 15% of all
genes. It has been reported that c-MYC modulates global
chromatin structure via its interaction with histone acetyl-
transferase (HAT) and SWI/SNF chromatin remodeling
complexes [61-63], which might be c-MYC function in the
SOX2/OCT3/4/NANOG complex. Supporting this
hypothesis, SOX2/OCT3/4/NANOG and c-MYC have
been found to share a large number of target genes in
ChIP-chip studies [10,39,53-55].
Furthermore, data shown in Fig. 6E suggests the presence
of a RUNX2/BMI-1/SMAD2/3 complex in undifferenti-
ated BG01V cells. Interestingly, the association of
SMAD2/3 with RUNX2 has been reported previously in B-
lymphocytes and human breast cancer cells [64,65]. BMI-
1 is part of the Polycomb-group complex [46,47] and a
known transcriptional repressor. SMAD2/3 and RUNX2
have been reported to act as both activators and repressors
[50,66]. Accordingly, many of the genes associated with
this RUNX2/BMI-1/SMAD2/3 complex in BG01V cells
(for example SMA,  IFNG,  GATA4  and  6,  MUC4,  FOS,
SNAIL, P21; data not shown) are not expressed in undif-
ferentiated ES cells [38,54], suggesting that this RUNX2/
BMI-1/SMAD2/3 complex plays a transcriptional repres-
sor role in undifferentiated BG01V cells.
Conclusion
In summary, our simplified basic ChIP and novel Sequen-
tial ChIP protocols were successfully tested with a variety
of antibodies and generated a number of novel observa-
tions for future studies. The basic ChIP assay combines
simplicity (avoidance of several commonly used steps),
speed (whole assay performed in 2 hours) and sensitivity
(using 20,000 cells). More importantly, promoter co-
occupancy data obtained with our novel Sequential ChIP
protocol indicates the existence of two TF complexes inBMC Biotechnology 2009, 9:59 http://www.biomedcentral.com/1472-6750/9/59
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human ES cells: SOX2/OCT3/4/NANOG/c-MYC and
RUNX2/BMI-1/SMAD2/3. This novel Sequential ChIP
protocol provides a significant improvement from previ-
ously described Sequential ChIP assays by combining two
methods of physical separation of the targeted DNA (cen-
trifugation and magnetism) and avoiding antibody-anti-
gen interaction disruption during the assay. Both
protocols might be useful for high-throughput ChIP-
based assays, which are expensive, labor intensive, require
complex statistical analysis, and might greatly benefit
from faster and straightforward ChIP assay and analysis
methodologies.
Methods
Cells and cell culture
Mouse ES cell line D3 was purchased from American Type
Culture Collection (ATCC) and cultured according to the
manufacturer's instructions. Undifferentiated human ES
cell line BG01V (Novocell) were cultured according to the
manufacturer's instructions, without feeder cells [38].
Endoderm differentiation of D3 cells was performed as
described previously [67].
Immunocytochemistry
Primary antibodies were used at 10 μg/ml. BG01V cells
were cultured in 24-well plates, fixed with 4% paraformal-
dehyde/PBS at room temperature (RT) for 20 min,
blocked and permeabilized with 0.1% Triton X-100, 1%
BSA, and 10% normal donkey serum in PBS, at RT, for 45
min. After blocking, cells were incubated with diluted pri-
mary antibody overnight at 4°C, followed by 5 μg/ml sec-
ondary antibody (anti-IgG-NL557, R&D Systems) at RT,
in the dark, for 1 hour. Cells were washed with PBS/0.1%
BSA between each step. No staining was obtained with
secondary antibody only, used as a negative control (data
not shown).
Reagents and antibodies
Anti-SOX2, NANOG, OCT3/4, c-MYC, PDX1, OLIG2,
RUNX2, SMAD2/3, KLF4, ERK1/2 and BMI-1 antibodies,
streptavidin magnetic beads (R&D Systems); antibody
specificity was determined previously with appropriate
controls by Western blotting and immunocytochemistry
[ref. [13] and data not shown]; Odyssey western blot
blocker buffer (LI-COR Biosciences); IDRdye 800 anti-
goat IgG antibody (Rockland Immunochemicals); phor-
bol-12-myristate-13-acetate (PMA), Chelex-100, lithium
chloride, sodium deoxycholate, leupeptin, phenyl-metha-
nessulfonyl-floride (PMSF), 37% formaldehyde, NP-40,
glycine, dimethyl-sulfoxide (DMSO), DAPI, aprotinin
(Sigma); AmpliTaq® Gold Polymerase PCR kit, dNTP mix
(Applied Biosystems); EXPRESS SYBR® GreenER™ qPCR
kit (Invitrogen); QIAQuick® DNA purification kit (Qia-
gen); 96-well PCR plates, 96-well plate foil (Eppendorf),
protein A-agarose beads (Thermo Scientific), and protein
G-agarose beads (Pierce).
Western blotting and Immunoprecipitation
Cells were lysed with 2× lysis buffer (2% NP-40, 100 mM
Tris-HCl, 300 mM NaCl, 4 mM EDTA, 2 mM sodium
vanadate, 10 μg/ml leupeptin, 2 mM PMSF, 10 μg/ml
aprotinin) and equal number of cell equivalents were sep-
arated by 10% SDS-PAGE. After Western transfer, nitrocel-
lulose membranes were blocked with Odyssey blocker/
PBS (1:1) for 1 hour, incubated with primary antibodies
for 30 min in Odyssey blocker/PBS/0.2% Tween, washed
with PBS/0.2% Tween 3× for 5 min, incubated for 30 min
with secondary fluorescent antibody (IDRdye 800 donkey
anti-goat IgG) in Odyssey blocker/PBS/0.2%Tween/
0.02%SDS, and washed with PBS/0.2%Tween 3× for 5
min. Fluorescence was detected and images captured with
an Odyssey infrared imager (LI-COR Biosciences). For
immunoprecipitation (IP) lysates were incubated with 5
μg of biotinylated anti-SOX2 antibody for 4 hrs at 4°C, for
each round of IP. Samples were incubated with 20 μL of
streptavidin magnetic beads (R&D Systems) for 30 min at
4°C, beads were collected with a magnet, and washed
with wash buffer (20 mM HEPES pH 7.6, 50 mM NaCl,
2.5 mM MgCl2, 0.1 mM EDTA, and 0.05% Triton X-100).
Basic ChIP Protocol
The basic ChIP assay (diagram shown in Fig. 1) is a com-
bination of sensitive and fast ChIP assays described previ-
ously [11,12] with some modifications. Cells were fixed
with 1% formaldehyde for 15 min (RT), quenched with
125 mM glycine for 5 min (RT), centrifuged and resus-
pended in Lysis Buffer (1% SDS, 10 mM EDTA, 50 mM
Tris, pH 8) containing protease inhibitors (10 μg/mL leu-
peptin, 10 μg/mL aprotinin, and 1 mM PMSF) and incu-
bated on ice (10 min). Initial samples consisted of about
1 × 106 cells in 0.5 mL of Lysis Buffer. Next samples were
sonicated (Heat Systems-Ultrasonic device) to shear chro-
matin to an average length of about 1 kb and transferred
to 1.5 mL tubes, microcentrifuged for 10 min (max
speed). Supernatants were collected in 1.5 mL tubes con-
taining 1 mL of the Dilution Buffer (0.01% SDS, 1.1% Tri-
ton, 1.2 mM EDTA, 167 mM NaCl, 17 mM Tris, pH 8).
Five μg of biotinylated primary antibodies were added,
samples were incubated (15 min) in an ultrasonic bath
(Branson), followed by addition of 50 μL of streptavidin
magnetic beads, incubated (30 min, 4°C) on a rotator
(Labnet Int.). Beads were collected with a magnet (R&D
Systems), washed 4× with 1 mL of each of four Wash Buff-
ers (Wash Buffer 1: 0.1% SDS, 1% Triton, 2 mM EDTA,
150 mM NaCl, 20 mM Tris, pH 8; Wash Buffer 2: 0.1%
SDS, 1% Triton, 2 mM EDTA, 500 mM NaCl, 20 mM Tris,
pH 8; Wash Buffer 3: 0.25 M LiCl, 1% NP-40, 1% deoxy-
cholate, 1 mM EDTA, 10 mM Tris, pH 8; Wash Buffer 4:
10 mM Tris, pH 8, 1 mM EDTA). After the last wash, 100
μL of a 10% Chelex-100 (Sigma)/PBS resin solution was
added to the beads, samples were boiled (10 min) in a
heat block, microcentrifuged (1 min, max speed), super-
natants transferred to a 1.5 mL tube, followed by the addi-BMC Biotechnology 2009, 9:59 http://www.biomedcentral.com/1472-6750/9/59
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tion of 120 μL of MilliQ water back to the beads,
microcentrifuged again (1 min, max speed), and the new
supernatant pooled with the previous one. DNA samples
were then cleaned up with QIAQuick kit®, resuspended in
50 μL of Wash Buffer 4 and 1 μL (containing about 20,000
cell equivalents) was used per PCR reaction. Experiments
were performed 3×, with independent samples.
Sequential ChIP
The Sequential ChIP protocol (diagram shown in Fig. 5)
was performed as follows. Samples were treated as above
until addition of the first antibody. Five μg of the first anti-
body was added, this time a non-biotinylated antibody,
incubated for 2 hrs to overnight at 4°C, followed by 50 μL
of protein G-agarose beads for 30 min at 4°C on a rotator
(Labnet Int.). Samples were then washed as described
above, using a microcentrifuge instead of a magnet to
pull-down the agarose beads. Subsequently the agarose
beads were resuspended in 1 mL of Dilution buffer. Five
μg of the second antibody was added, this time a bioti-
nylated antibody, incubated for 2 hrs to overnight at 4°C,
followed by incubation with magnetic streptavidin beads.
Beads were washed as described above, using a magnet,
and the final DNA samples were obtained as described
above (basic ChIP protocol). Experiments were per-
formed 3×, with independent samples.
PCR and Densitometric Image Analysis
DNA samples, from ChIP assays or input DNA (0.1% of
the sample used for the ChIP assay), primers (1 μM, IDT)
and DMSO (5%) were added to the additional PCR rea-
gents (AmpliTaq® Gold Polymerase PCR kit and dNTP
mix) in a 50 μL reaction volume and subjected to the fol-
lowing cycle: 95°C/9 min, 43× (95°C/1 min, 60°C/1
min), and 60°C/10 min, using 96-well plates and an
Eppendorf Mastercycler®. PCR products were subjected to
a 1.5% agarose gel electrophoresis, visualized with Ethid-
ium bromide staining and photographed. Images were
saved as TIFF files for analysis with ImageJ. All primers
have been validated previously (Table 1). Signal intensi-
ties from PCR data obtained from ChIP assays or from
whole cell lysates (Input DNA) were quantified from the
TIFF images with ImageJ software (National Institutes of
Health; http://rsbweb.nih.gov/ij/), as previously
described [68] with some modifications. Initially images
were transformed to 16-bit-type images. The threshold
function was set to black and white type of image to elim-
inate background interference. Threshold limits were set
to compensate possible saturation interference. The rec-
tangle tool was used to draw the area for measurement
around the PCR bands and the same rectangle tool was
moved to each band in the blot. Area, area fraction and
mean gray values were taken. Mean gray values were used
as a measure of relative number of pixels. Fold enrichment
= ChIP/Input DNA. For each TF three independent ChIP
experiments were performed. Average and standard devi-
ations (SD) were calculated based on the signal intensities
from each experiment.
Real-time PCR (rtPCR)
DNA samples, from ChIP assays or input DNA (0.1% of
the sample used for the ChIP assay), and primers (200
nM, IDT) were added to the additional rtPCR reagents
(EXPRESS SYBR® GreenER™ qPCR kit) in a 20 μL reaction
volume and subjected to the following cycle: 50°C/2 min,
95°C/2 min, 40× (95°C/15 sec, 60°C/1 min), using ABI
7900 HT or Cepheid Smart rtPCR instruments. No tem-
plate (primers only) reactions were used for normaliza-
tion. Each sample was amplified in triplicate. Three
independent experiments were performed. Average and
SD were calculated based on relative copy numbers from
each experiment.
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